Author:
Wang Huwen,Jiang Xiaoting,Chan Kate Ching Ching,Wei Yuchen,Hung Chi Tim,Chan Renee Wan Yi,Li Conglu,Leung Eman Yee Man,Yam Carrie Ho Kwan,Chow Tsz Yu,Zhao Shi,Guo Zihao,Li Kehang,Wang Ziqing,Yeoh Eng Kiong,Chong Ka Chun
Abstract
Abstract
Background
The available evidence presented inconsistencies and inconclusive findings regarding the associations between co-existing asthma and mortality among COVID-19 patients. The objective of the current study is to investigate the relationship between asthma and severe outcomes after SARS-CoV-2 Omicron infection in an infection-naïve population.
Methods
A retrospective cohort study using propensity score matching was conducted. The COVID-19 patients requiring hospitalisation in Hong Kong from January 1, 2022, to November 13, 2022, an Omicron-predominated period, were identified. Severe clinical outcomes were defined as ICU admission and inpatient death after the first positive PCR results as well as a composite outcome of both.
Results
Of the 74,396 hospitalised COVID-19 patients admitted, 1,290 asthma patients and 18,641 non-asthma patients were included in the matched cohort. The rates of death and the composite outcome were 15·3% and 17·2%, respectively, among the non-asthma patients,12·2% and 13·6%, respectively, among the asthma patients, with adjusted hazard ratios equal to 0·775 (95% CI: 0·660–0·909) and 0·770 (95% CI: 0·662–0·895), respectively. The negative association was more apparent in the elderly and female groups. Asthma remained a factor that lowered the risk of disease severity even though the patients were not fully vaccinated with at least two doses.
Conclusions
We used real-world data to demonstrate that asthma was not a risk factor for COVID-19 severity of the infections of Omicron variant, even though the patients were not fully vaccinated.
Funder
Health and Medical Research Fund
Collaborative Research Fund of University Grants Committee
National Natural Science Foundation of China
Group Research Scheme
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. The Global Asthma Report. Auckland: Global Asthma Network; 2018. http://globalasthmareport.org/2018/resources/Global_Asthma_Report_2018.pdf. Accessed 20 Nov 2023.
2. Busse WW, Lemanske RF, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. The Lancet. 2010;376(9743):826–34.
3. US Centers for Disease Control and Prevention. Brief Summary of the Association between Underlying Conditions and Severe COVID-19: Asthma. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/pdf/K-Brief-Summary-of-Findings-on-the-Association-Between-Asthma-and-SevereCOVID-19-Outcomes-508.pdf. Accessed 20 Nov 2023.
4. Adir Y, Saliba W, Beurnier A, Humbert M. Asthma and COVID-19: an update. Eur Respir Rev. 2021;30(162):210152.
5. Skevaki C, Karsonova A, Karaulov A, Xie M, Renz H. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020;146(6):1295–301.